Appendix 4C and Activities Report - March 2023 Quarter
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix Preclinical Development of Radiolabelled Olaratumab
- Illuccix European Marketing Authorisation Application Update
- FDA approval of expanded indication of Illuccix in the US
- 2022 Full Year Results Presentation
- Appendix 4E and 2022 Annual Report
Later from Telix Pharmaceuticals
- Q1 2023 Business update to accompany quarterly results
- Telix Accelerates AI Development with Dedicaid Acquisition
- Presentation to Accompany AI Development Program Update
- ZIRCON Data Presented at AUA Confirms Efficacy in 2cm Masses
- Annual General Meeting - Chairman and CEO Addresses
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals